YS Biopharma Co. Ltd.

As of May 10, 2024, YS Biopharma Co. Ltd. is considered overvalued and risky due to its negative earnings performance, a concerning -22.61% Return on Equity, and a year-to-date stock decline of -71.97%, contrasting sharply with its peers and the S&P 500.

As of June 4, 2025, the technical trend is bearish, supported by bearish daily moving averages and KST, despite a mildly bullish MACD on longer time frames, indicating mixed signals and a lack of upward momentum compared to the S&P 500.

YS Biopharma Co. Ltd. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $19 million and a net loss of $25 million for Q1 2024, with a market cap of $18.51 million. Key financial metrics include a debt equity ratio of 0.30 and a return on equity of -22.61%.